Lazertinib

Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC

Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC

SG Tylor

In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...